Key Players
Competitive Landscape
Commercial dermatology companies and clinical-stage immune developers compete alongside phototherapy manufacturers and cell-based procedure providers in the vitiligo market.
Investment in vitiligo has shifted toward oral immune programs and regional treatment support since 2025. STRATA appointed EKPAC as XTRAC distributor in China in June 2026 across more than twenty-five provinces. Teva secured up to USD 500 million from Royalty Pharma in January 2026 for TEV-'408 development. Dermatologists now compare companies through repigmentation evidence and dependable service access during prolonged treatment courses.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| STRATA appointed EKPAC as exclusive XTRAC distributor in China, June 2026: coverage across more than 25 provinces | Clinics need authorized maintenance and trained application support | Excimer distribution shifts toward service-backed regional networks | XTRAC placements with parts and service support for targeted phototherapy |
| Teva and Royalty Pharma signed a funding agreement, January 2026: up to USD 500 million for TEV-'408 | Extensive disease requires options beyond practical topical coverage | Specialist financing supports mid-stage immune programs | Quarterly systemic therapy for nonsegmental vitiligo |
| CLINUVEL recruited 200 patients for Phase III CUV105, May 2025 | Dermatologists need repigmentation evidence across darker skin types | Programs combine systemic peptides with supervised narrowband UVB | Combination protocols linking medicine with recurring light treatment |
Incyte, AbbVie, Pfizer, AVITA Medical and Alys Pharmaceuticals, Inc. compete through approved topical medicine, systemic programs, cell-based repigmentation and an earlier topical platform outside the three selected developments.
Source: Future Market Insights, Vitiligo Market and Phototherapy Equipment Market Reports, 2026-2036.
Incyte and STRATA cover topical medicine, oral development and excimer therapy alongside AVITA's approved cell procedure despite paused commercial investment.
Who provides marketed treatment pathways for vitiligo?
Incyte provides approved topical ruxolitinib for eligible nonsegmental vitiligo patients in the United States and Europe. STRATA supplies XTRAC excimer systems through established clinic networks serving targeted light-based treatment for eligible vitiligo lesions. AVITA retains an approved RECELL procedure for stable vitiligo lesions in the United States despite limited reimbursement support.
Which companies are advancing systemic vitiligo programs?
Incyte reported positive Phase 3 povorcitinib results in April 2026 and AbbVie received a positive CHMP opinion in June 2026. Pfizer completed TRANQUILLO in February 2026, and Teva prepared TEV-'408 for Phase 2b development.
Which companies support light-based or combination treatment?
STRATA supplies 308-nm excimer systems with pediatric combination evidence involving oral JAK inhibitors in progressive vitiligo. CLINUVEL evaluates afamelanotide with narrowband UVB and AVITA provides a cell-based procedure for selected stable lesions.
Which companies cover localized and extensive disease pathways?
Incyte covers localized topical treatment and an oral program for broader nonsegmental disease across different body areas. AbbVie, Pfizer and Teva pursue systemic candidates as STRATA and AVITA address clinic-based treatment for stable or treatment-resistant lesions.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Incyte Corporation | United States, Europe and Canada | Approved topical ruxolitinib and positive Phase 3 oral povorcitinib program. |
| AbbVie Inc. | Global clinical development | Upadacitinib Phase 3 evidence and positive CHMP opinion for nonsegmental vitiligo. |
| Pfizer Inc. | Global clinical development | Ritlecitinib TRANQUILLO Phase 3 program in adults and adolescents. |
| Teva Pharmaceutical Industries Ltd. | Global clinical development | Anti-IL-15 TEV-'408 with planned quarterly dosing and Phase 2b development. |
| STRATA Skin Sciences, Inc. | United States and China distribution | XTRAC 308-nm excimer systems, pediatric combination evidence and authorized service network. |
| AVITA Medical, Inc. | United States approval | FDA-approved RECELL procedure for stable vitiligo; further commercial investment paused in 2025 as reimbursement remained uncertain. |
| CLINUVEL Pharmaceuticals Ltd. | Europe and North America trial network | CUV105 Phase III study of afamelanotide combined with narrowband UVB. |
| Alys Pharmaceuticals, Inc. | Vitiligo geography not disclosed | Trans-epidermal ALY-101 formulation disclosed for vitiligo; clinical-stage entry remained planned for 2026. |
Research Methodology
The companies shown here illustrate market structure and do not rank commercial performance or market share. Inclusion requires current evidence of an approved treatment, a direct clinical program, a phototherapy system or a vitiligo procedure. Regulatory records, official company announcements and clinical registries document geography plus treatment stage and approved scope. The 42.0% topical treatment share is an FMI estimate for the 2026 alone.
